Gastrointestinal stromal tumor surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
{{Gastrointestinal stromal tumor}} | {{Gastrointestinal stromal tumor}} | ||
* Most small GISTs (<5 and especially <2 cm) with a low rate of [[mitosis]] (<5 dividing cells per 50 high-power fields) are [[benign]] and,after surgery, do not require [[adjuvant therapy]]. | |||
* Larger GISTs (>5 cm), and especially when the cell division rate is high (>6 [[mitosis|mitoses]]/50 HPF), may disseminate and/or recur. | |||
* Until recently, GISTs were notorious for being resistant to [[chemotherapy]], with a success rate of <5%. Recently, the ''c-kit'' [[tyrosine kinase]] inhibitor [[imatinib]], a drug initially marketed for [[chronic myelogenous leukemia]], was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases. | |||
* Patients who become refractory on imatinib may respond to the multiple tyrosine kinase inhibitor [[sunitinib]] (marketed as Sutent). | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Line 10: | Line 15: | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 19:37, 31 August 2015
Gastrointestinal stromal tumor Microchapters |
Differentiating Gastrointestinal stromal tumor from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Gastrointestinal stromal tumor surgery On the Web |
American Roentgen Ray Society Images of Gastrointestinal stromal tumor surgery |
Directions to Hospitals Treating Gastrointestinal stromal tumor |
Risk calculators and risk factors for Gastrointestinal stromal tumor surgery |
- Most small GISTs (<5 and especially <2 cm) with a low rate of mitosis (<5 dividing cells per 50 high-power fields) are benign and,after surgery, do not require adjuvant therapy.
- Larger GISTs (>5 cm), and especially when the cell division rate is high (>6 mitoses/50 HPF), may disseminate and/or recur.
- Until recently, GISTs were notorious for being resistant to chemotherapy, with a success rate of <5%. Recently, the c-kit tyrosine kinase inhibitor imatinib, a drug initially marketed for chronic myelogenous leukemia, was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases.
- Patients who become refractory on imatinib may respond to the multiple tyrosine kinase inhibitor sunitinib (marketed as Sutent).
References